Warning letter
Chongqing Lummy Pharmaceutical Co. Ltd.: warning letter of Jun 21, 2016
FDA warning letter 494702 · Center for Drug Evaluation and Research
Key facts
| Reference number | 494702 |
|---|---|
| Company | Chongqing Lummy Pharmaceutical Co. Ltd. |
| Subject | CGMP/Active Pharmaceutical Ingredient (API)/Finished Pharmaceuticals/Adulterated |
| Issue date | Jun 21, 2016 |
| Posted date | Jun 28, 2016 |
| Issuing office | Center for Drug Evaluation and Research |
| Product type | Drugs |
| Inspection city | Chongqing |
| Inspection start date | Mar 14, 2016 |
| Letter on fda.gov | web.archive.org |
At a glance
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: